HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

2- (4- (2- (5- (1- (3,5- dichloropyridin- 4- yl)ethoxy)- 1H- indazol- 3yl)vinyl)- 1H- pyrazol- 1- yl)ethanol

structure in first source

Also Known As:

LY2874455

Networked: 9 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 207
- 1-Ring Heterocyclic Compounds
  - Azoles: 2199
    - Pyrazoles: 61
      - Indazoles: 183
        2-(4-(2-(5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1H-indazol-3yl)vinyl)-1H-pyrazol-1-yl)ethanol: 9
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Indazoles: 183
      - 2-(4-(2-(5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1H-indazol-3yl)vinyl)-1H-pyrazol-1-yl)ethanol: 9

Experts

1.	Li, Huihui: 2 articles (05/2024 - 03/2024)
2.	Lu, Kefeng: 2 articles (05/2024 - 03/2024)
3.	Zhou, Jiao: 2 articles (05/2024 - 03/2024)
4.	Chen, Shanze: 1 article (03/2024)
5.	Jiang, Gaoyue: 1 article (03/2024)
6.	Li, Chunxia: 1 article (03/2024)
7.	Lu, Meng: 1 article (03/2024)
8.	Alavi, Shahryar: 1 article (01/2021)
9.	Dehghanian, Fariba: 1 article (01/2021)
10.	Anakura, Mai: 1 article (09/2019)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2017 - "A Phase 1 Study of LY2874455, an Oral Selective pan-FGFR Inhibitor, in Patients with Advanced Cancer." 01/01/2021 - "Molecular mechanisms of the anti-cancer drug, LY2874455, in overcoming the FGFR4 mutation-based resistance." 01/01/2017 - "LY2874455 has an RP2D of 16 mg BID and demonstrated good tolerability and activity in solid-organ cancer patients. " 09/14/2019 - "Inhibition of FGFR using the clinically available pan-FGFR inhibitor LY2874455 sensitized multiple cancer cell lines to carbon ions at 3 Gy (RBE: relative biological effectiveness), the daily dose prescribed to the patient. "
2.	Liposarcoma 01/01/2019 - "Preclinical Evaluation of the Pan-FGFR Inhibitor LY2874455 in FRS2-Amplified Liposarcoma." 01/01/2019 - "Conclusion: Our study supports LY2874455 as a better therapy than NVP-BGJ398 for FRS2-amplified liposarcoma, and a clinical trial is warranted."
3.	Acute Lung Injury 03/01/2024 - "In mice, LY2874455 protected against LPS-induced acute lung injury and dextran sulfate sodium (DSS)-induced colitis and caused low levels of proinflammatory cytokines and immunoproteasomes. "
4.	Hyperphosphatemia 01/01/2017 - "LY2874455 was generally well tolerated; most toxicities were grade 1 or 2; most frequent were hyperphosphatemia, diarrhea, and stomatitis. "
5.	Stomatitis 01/01/2017 - "LY2874455 was generally well tolerated; most toxicities were grade 1 or 2; most frequent were hyperphosphatemia, diarrhea, and stomatitis. "

Related Drugs and Biologics

1.	infigratinib
2.	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)
3.	Dextran Sulfate
4.	Cytokines
5.	Lipopolysaccharides
6.	Ions
7.	Carbon

Related Therapies and Procedures

1.	Therapeutics